Related Experiment Video
Updated: Jun 6, 2026
12:44
The In ovo CAM-assay as a Xenograft Model for Sarcoma
Published on: July 17, 2013
Angiosarcoma: state of the art and perspectives
Nicolas Penel1, Sandrine Marréaud, Yves-Marie Robin
1EORTC Headquarters, Belgium. n-penel@o-lambret.fr
Critical Reviews in Oncology/Hematology
|November 9, 2010
Summary
Angiosarcoma (AS) is a rare cancer. Treatment for localized AS involves surgery and radiotherapy, while advanced cases may benefit from chemotherapy and anti-angiogenic agents.
Area of Science:
- Oncology
- Sarcoma Research
- Medical Literature Review
Background:
- Angiosarcoma (AS) comprises 1% of adult soft tissue sarcomas.
- Established risk factors include chronic lymphedema and prior radiotherapy.
- AS presents with heterogeneous clinical manifestations.
Purpose of the Study:
- To review available data on angiosarcoma.
- To summarize current treatment strategies and research findings.
- To identify future research directions for angiosarcoma.
Main Methods:
- Literature review of published data on angiosarcoma.
- Analysis of clinical presentations, risk factors, and treatment outcomes.
- Evaluation of recent clinical trials and biological evidence.
Main Results:
- Localized AS treatment: surgical resection and adjuvant radiotherapy.
- No strong evidence for adjuvant chemotherapy in localized AS.
- Metastatic/advanced AS: doxorubicin and weekly paclitaxel show promise for progression-free survival.
- Clinical trials for rare diseases like AS are feasible.
- Growing evidence supports the role of angiogenic factors in AS.
Conclusions:
- Current treatment for localized angiosarcoma relies on surgery and radiotherapy.
- Chemotherapy options for advanced angiosarcoma are limited but evolving.
- Anti-angiogenic agents represent a promising therapeutic avenue for angiosarcoma, potentially in combination with chemotherapy.
Related Concept Videos
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
02:49Cancer Therapies
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
01:21Cancer Survival Analysis
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
01:24Regulation of Angiogenesis and Blood Supply
Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits. Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl hydroxylase and factor...